{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:51:57Z","timestamp":1792043517103,"version":"4.4.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Relapse after treatment withdrawal remains a major challenge in psoriasis. Despite high rates of clinical clearance with modern systemic therapies, durable off-therapy control is uncommon, and recurrence often reappears at previously affected sites. Current models centered on resolved-skin inflammatory memory explain important aspects of local recall, but may not fully account for the heterogeneity of relapse timing, pattern and durability seen across patients. Here, we review psoriasis relapse through a clinically oriented multilevel framework that integrates three interacting dimensions: an antigenic dimension, blood-accessible relapse-associated signals and programs, and tissue permissiveness. Presentation-level antigen evidence raises the possibility that selected psoriatic phenotypes are associated with distinct upstream inflammatory programs, although direct links to relapse remain unproven. Circulating skin-homing memory populations, relapse-associated blood candidates and resident-derived mobile programs suggest, but do not establish, that relapse-relevant memory may remain accessible outside the skin during remission. At the tissue level, molecular scarring, epidermal tissue-resident memory T cells and stromal\u2013epithelial support help explain why recurrence is preferentially re-executed in previously involved skin. We propose the Antigen\u2013Blood\u2013Tissue model as a falsifiable structure for interpreting relapse heterogeneity rather than a closed explanation of recurrence. Clinically, this framework suggests that visible clearance and biological stability should not be considered interchangeable. It also supports the view that remission may represent a biologically variable state, and that prospective studies aligned to treatment tapering or withdrawal will be needed to determine whether biological stability can eventually be defined beyond clinical remission and related prospectively to relapse outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1875991","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:56:56Z","timestamp":1788789416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From clinical remission to biological stability in psoriasis: an antigen\u2013blood\u2013tissue framework for relapse stratification"],"prefix":"10.3389","volume":"17","author":[{"given":"Zeyun","family":"Qiao","sequence":"first","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]},{"name":"Shanxi University of Chinese Medicine","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]},{"name":"Department of Dermatology and Cosmetology, Chongqing Traditional Chinese Medicine Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingsheng","family":"Hao","sequence":"additional","affiliation":[{"name":"Clinical Medical College, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]},{"name":"Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01229-6","article-title":"Comparison of drug-free remission after the end of phase III trials of three different anti-IL-23 inhibitors in psoriasis","volume":"14","author":"Hsieh","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: from remission to recurrence","volume":"154","author":"Francis","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/jid.2010.280","article-title":"Resolved psoriasis lesions retain expression of a subset of disease-related genes","volume":"131","author":"Su\u00e1rez-Fari\u00f1as","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s40257-024-00887-8","article-title":"Predicting the time to relapse following withdrawal from different biologics in patients with psoriasis who responded to therapy: a 12-year multicenter cohort study","volume":"25","author":"Huang","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00679-y","article-title":"Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review","volume":"23","author":"Masson Regnault","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1488096","article-title":"Development and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics","volume":"11","author":"Huang","year":"2024","journal-title":"Front Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1038\/s41467-025-56719-8","article-title":"GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets","volume":"16","author":"Dand","year":"2025","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.008","article-title":"The quest for psoriasis autoantigens: genetics meets immunology in the melanocyte","volume":"137","author":"Elder","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512310","article-title":"The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options","volume":"24","author":"Patel","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adx0637","article-title":"Immunopeptidome analysis reveals SERPINB3 as an autoantigen driving eczematized psoriasis","volume":"11","author":"Jargosch","year":"2025","journal-title":"Sci Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-024-00482-x","article-title":"Immunopeptidomics for autoimmunity: unlocking the chamber of immune secrets","volume":"11","author":"Arshad","year":"2025","journal-title":"NPJ Syst Biol Appl"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100563","article-title":"Sensitive, high-throughput HLA-I and HLA-II immunopeptidomics using parallel accumulation-serial fragmentation mass spectrometry","volume":"22","author":"Phulphagar","year":"2023","journal-title":"Mol Cell Proteomics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104930","article-title":"Complimentary electrostatics dominate T-cell receptor binding to a psoriasis-associated peptide antigen presented by human leukocyte antigen C\u221706:02","volume":"299","author":"Anand","year":"2023","journal-title":"J Biol Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105518","article-title":"Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes","volume":"23","author":"Tsai","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1541776","article-title":"Beyond the dichotomy: understanding the overlap between atopic dermatitis and psoriasis","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14991","article-title":"Eczematized psoriasis \u2013 a frequent but often neglected variant of plaque psoriasis","volume":"21","author":"Lauffer","year":"2023","journal-title":"JDDG: J der Deutschen Dermatologischen Gesellschaft"},{"key":"B21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jid.2023.06.194","article-title":"Genomic profiling of the overlap phenotype between psoriasis and atopic dermatitis","volume":"144","author":"Kim","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/17103568251378145","article-title":"Psoriasis and atopic dermatitis overlap: pathogenesis and therapeutic considerations for the clinician","author":"Marzouk","year":"2026","journal-title":"Dermatitis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1016\/j.jid.2024.04.011","article-title":"SERPINB3\/B4 is increased in psoriasis and rosacea lesions and has proinflammatory effects in mouse models of these diseases","volume":"144","author":"Xiao","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1388690","article-title":"Discovery of biomarkers in the psoriasis through machine learning and dynamic immune infiltration in three types of skin lesions","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1038\/ncomms6621","article-title":"The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis","volume":"5","author":"Lande","year":"2014","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160258","article-title":"Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a","volume":"213","author":"Cheung","year":"2016","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413387","article-title":"Keratinocyte-mediated antigen presentation in psoriasis: preliminary insights from in vitro studies","volume":"25","author":"Zima","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090480","article-title":"Self-RNA\u2013antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8","volume":"206","author":"Ganguly","year":"2009","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41467-019-13756-4","article-title":"Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis","volume":"11","author":"Herster","year":"2020","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100686","article-title":"ERAP1 controls the autoimmune response against melanocytes in psoriasis by generating the melanocyte autoantigen and regulating its amount for HLA-C*06:02 presentation","volume":"207","author":"Arakawa","year":"2021","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149485","article-title":"Phospholipase activity of acyloxyacyl hydrolase induces IL-22-producing CD1a-autoreactive T cells in individuals with psoriasis","volume":"52","author":"Singh","year":"2022","journal-title":"Eur J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70518","article-title":"Single\u2010cell transcriptomics reveal circulating skin\u2010homing CLA+ CTSW+ cytotoxic CD4+ T cells contribute to relapse of psoriasis","volume":"15","author":"Chiu","year":"2025","journal-title":"Clin Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/jid.2012.418","article-title":"Streptococcus induces circulating CLA+ memory T-cell-dependent epidermal cell activation in psoriasis","volume":"133","author":"Ferran","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01688.x","article-title":"The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease","volume":"126","author":"Sigmundsd\u00f3ttir","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aav8995","article-title":"Human CD4+CD103+ cutaneous resident memory T cells are found in the circulation of healthy individuals","volume":"4","author":"Klicznik","year":"2019","journal-title":"Sci Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210417","article-title":"Human resident memory T cells exit the skin and mediate systemic Th2-driven inflammation","volume":"218","author":"Strobl","year":"2021","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.6.1461","article-title":"The cutaneous lymphocyte antigen is a skin lymphocyte homing receptor for the vascular lectin endothelial cell-leukocyte adhesion molecule 1","volume":"174","author":"Berg","year":"1991","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.150.3.1122","article-title":"Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells","volume":"150","author":"Picker","year":"1993","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.0906-6705.2004.00177.x","article-title":"Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin","volume":"13","author":"Sigmundsdottir","year":"2004","journal-title":"Exp Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1023\/B:JOCI.0000029107.47085.1b","article-title":"Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1\/T helper 2 balance in psoriatic patients","volume":"24","author":"Rentenaar","year":"2004","journal-title":"J ClinImmunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12093","article-title":"Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis","volume":"22","author":"J\u00f3kai","year":"2013","journal-title":"Exp Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.048","article-title":"Microbe-dependent induction of IL-9 by CLA+ T cells in psoriasis and relationship with IL-17A","volume":"138","author":"Ruiz-Romeu","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14113","article-title":"IL-15 and IL-23 synergize to trigger Th17 response by CLA+ T cells in psoriasis","volume":"29","author":"de Jes\u00fas-Gil","year":"2020","journal-title":"Exp Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3492","article-title":"Effect of costimulatory blockade with abatacept after ustekinumab withdrawal in patients with moderate to severe plaque psoriasis: the PAUSE randomized clinical trial","volume":"157","author":"Harris","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1038\/s41598-019-41609-z","article-title":"Assessment and clinical relevance of serum IL-19 levels in psoriasis and atopic dermatitis using a sensitive and specific novel immunoassay","volume":"9","author":"Konrad","year":"2019","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0723-4","article-title":"Tissue-resident memory CD8+ T cells shape local and systemic secondary T cell responses","volume":"21","author":"Behr","year":"2020","journal-title":"Nat Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.02.030","article-title":"Resident T cells in resolved psoriasis steer tissue responses that stratify clinical outcome","volume":"138","author":"Gallais S\u00e9r\u00e9zal","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk","year":"2014","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054556","article-title":"Psoriatic resolved skin epidermal keratinocytes retain disease-residual transcriptomic and epigenomic profiles","volume":"24","author":"Ghaffarinia","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi2848","article-title":"A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response","volume":"9","author":"Wu","year":"2024","journal-title":"Sci Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/bjd.16412","article-title":"HLA-C*06 and psoriasis: susceptibility, phenotype, course and response to treatment","volume":"178","author":"Borroni","year":"2018","journal-title":"Br J Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103140","article-title":"The HLA-Cw6 dilemma: Is it really an outcome predictor in psoriasis patients under biologic therapy? A monocentric retrospective analysis","volume":"9","author":"Burlando","year":"2020","journal-title":"J Clin Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00949-5","article-title":"Disease modification in psoriasis: Future prospects for long-term remission","volume":"26","author":"Ranzinger","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14072","article-title":"Sites of recurrence in patients following clearance of psoriasis with biologic therapy","volume":"31","author":"No","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00766-z","article-title":"Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)","volume":"41","author":"Benezeder","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.09.012","article-title":"Curing psoriasis","volume":"144","author":"Lwin","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.ijd_167_24","article-title":"Biomarkers in psoriasis: The future of personalised treatment","volume":"69","author":"Kar","year":"2024","journal-title":"Indian J Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: The GUIDE randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1369805","article-title":"Dose reduction of biologics in patients with plaque psoriasis: a review","volume":"15","author":"van Riel","year":"2024","journal-title":"Front Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: A scoping review","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2025.501134","article-title":"Latin American consensus on tapering of biological therapy in psoriasis","volume":"100","author":"Londo\u00f1o-Garc\u00eda","year":"2025","journal-title":"Anais Brasileiros Dermatologia"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13378","article-title":"Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active psoriasis and localized with keratinocytes, dendritic cells and other leukocytes","volume":"26","author":"Fuentes-Duculan","year":"2017","journal-title":"Exp Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:56:58Z","timestamp":1788789418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1875991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":67,"alternative-id":["10.3389\/fimmu.2026.1875991"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1875991","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1875991"}}